Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Dec 22nd, 4:58 PM EST
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | N/A - N/A |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
As of December 18, 2025, the landscape of the global automotive industry is undergoing a seismic shift, and at the center of this transformation stands the newly restructured Tata Motors ecosystem. Known formally as Tata Motors Limited (NSE: TATAMOTORS | BSE: 500570), the company has recently completed one of the most significant corporate restructuring exercises [...]
Via PredictStreet · December 18, 2025
As of December 17, 2025, QuantumScape Corporation (NYSE: QS), soon to be listed on Nasdaq from December 23, 2025, stands as a prominent innovator in the electric vehicle (EV) battery sector. Headquartered in San Jose, California, the company is singularly focused on the development and commercialization of next-generation solid-state lithium-metal batteries. QuantumScape’s ambition is to [...]
Via PredictStreet · December 17, 2025
As of December 12, 2025, Plug Power Inc. (NASDAQ: PLUG) stands as a pivotal player in the burgeoning green hydrogen economy, dedicated to developing comprehensive hydrogen fuel cell and electrolyzer systems. The company's strategic focus extends beyond the mere manufacturing of fuel cells to orchestrating an entire hydrogen value chain, encompassing production, liquefaction, storage, transport, [...]
Via PredictStreet · December 12, 2025
US House Passes Republican Healthcare Bill, ACA Extension Left Out
The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of the ACA tax credits that were at the heart of the recent government shutdown. This bill now heads to the Senate for consideration.
Via Investor Brand Network · December 19, 2025
Soligenix Inc. (NASDAQ: SNGX) Extends SGX302 Clinical Success in Phase 2A Psoriasis Study
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The updated findings highlight clinical improvements with an optimized gel formulation of the investigational therapy, underscoring the potential of SGX302 as a noncarcinogenic, photodynamic treatment.
Via Investor Brand Network · December 22, 2025
Date: 12/11/2025 1. Introduction QuantumScape Corporation (NYSE: QS, soon to be Nasdaq: QS), headquartered in San Jose, California, stands at the forefront of developing next-generation solid-state lithium-metal battery technology. As of December 11, 2025, the company remains a significant focal point in the market due to its advanced technological breakthroughs, strategic milestones, and the transformative [...]
Via PredictStreet · December 11, 2025
Date: December 11, 2025 1. Introduction Qualcomm (NASDAQ: QCOM), headquartered in San Diego, California, stands as a foundational technology leader in the wireless industry. The company designs semiconductors, software, and services critical to global mobile communication standards, including 5G and 4G. As of December 2025, Qualcomm is in the midst of a significant strategic transformation, [...]
Via PredictStreet · December 11, 2025
Plug Power stock has performed poorly over the past few years, but that could change soon.
Via The Motley Fool · December 20, 2025
As the final weeks of 2025 unfold, the German equity market finds itself at a critical crossroads. While current industrial production figures remain sluggish, a wave of forward-looking optimism is sweeping through the financial district in Frankfurt. Leading the charge is European brokerage powerhouse Kepler Cheuvreux, which has just released
Via MarketMinute · December 19, 2025
Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat
A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, is developing a vaccine candidate known as RiVax(R) to protect against ricin exposure, positioning the company’s work at the center of biodefense preparedness as public awareness of ricin’s lethality grows.
Via Investor Brand Network · December 19, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Launch Open-Label Extension Study of Buntanetap in Parkinson Disease
Annovis Bio (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data to support further evaluation of buntanetap’s potential as a disease-modifying therapy for neurodegenerative disorders.
Via Investor Brand Network · December 19, 2025
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration
Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced computing, and cybersecurity technologies that may support Nutriband’s research and long-term product development initiatives. The company said the discussions will focus on areas such as secure AI and analytics platforms for regulated pharmaceutical data, data integrity frameworks supporting abuse-deterrent technologies, and advanced modeling and simulation enabled by quantum-ready infrastructure, while emphasizing that the LOI does not establish a partnership or commercial relationship and that any future collaboration would be subject to further review, due diligence, and definitive agreements.
Via Investor Brand Network · December 19, 2025
As 2025 draws to a close, the artificial intelligence investment landscape has undergone a profound transformation. The "generative hype" of previous years has matured into a disciplined focus on the infrastructure of trust and the physical manifestation of intelligence. This shift is most visible in the surge of specialized Exchange-Traded Funds (ETFs) targeting AI Security [...]
Via TokenRing AI · December 18, 2025
As 2025 draws to a close, the global financial landscape has been fundamentally reshaped by what analysts are calling the "Gold and Silver Revolution." In a year marked by geopolitical volatility and a tectonic shift in industrial demand, precious metals have staged a historic rally that has left traditional equity
Via MarketMinute · December 18, 2025
Chronic Inflammation Could Be the Missing Key to Understanding Long Covid
In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human Services. For a long time, the scientific community has struggled to find out why some individuals who got infected with Covid-19 recovered fully while others developed lingering symptoms that came to be described as long Covid. Now a new study has established that the key driver among people with long Covid could be chronic inflammation and this opens new pathways to treating the condition .
Via Investor Brand Network · December 18, 2025
The automotive industry has reached a definitive tipping point as of late 2025. The era of the internal combustion engine’s mechanical complexity has been superseded by a new era of silicon-driven sophistication. We are no longer witnessing the evolution of the car; we are witnessing the birth of the "Software-Defined Vehicle" (SDV), where the value [...]
Via TokenRing AI · December 18, 2025
Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology
In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.
Via Investor Brand Network · December 17, 2025
In a pivotal move set to redefine the landscape of artificial intelligence in the automotive sector, leading research and development organizations, imec and Japan's Advanced SoC Research for Automotive (ASRA), are spearheading a collaborative effort to standardize chiplet designs for advanced automotive AI applications. This strategic partnership addresses a critical need for interoperability, scalability, and [...]
Via TokenRing AI · December 16, 2025
Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment
A new study done in India has produced results that bring into question the longstanding assumption that treating cancer requires tumors to be destroyed. The researchers attained remarkable results by using another approach, treating the tumor rather than attacking it, and their approach was effective in taming the aggressiveness of glioblastoma while also toning down many biomarkers that indicate the severity of the cancer.
Via Investor Brand Network · December 16, 2025
Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics
The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates fall to just 3% . These economics have created a bottleneck that leaves patients waiting years for new treatments that rarely arrive.
Via Investor Brand Network · December 15, 2025
The pre-owned vehicle industry in Riverside is experiencing a shift as TM Motors redefines what buyers should expect from their car-purchasing experience. Located at 10100 Arlington Ave., the dealership has built a reputation for prioritizing customer satisfaction over high-pressure sales tactics, creating a welcoming environment for those seeking quality transportation options.
Via AB Newswire · December 14, 2025
Shares of Quantum Computing Inc. stock are plummeting.
Via The Motley Fool · December 13, 2025
Study Highlights Increasing Cases of Breast Cancer in Younger Women
A study that involved an analysis of patient records in New York has discovered that breast cancer, and especially aggressive forms of this cancer, is occurring at a higher rate among younger women aged below 40. This group is currently regarded as low risk for breast cancer by the existing screening guidelines, and this calls for a review of those guidelines.
Via Investor Brand Network · December 12, 2025
Health Experts Suggest How Public Trust Can Be Restored in US Healthcare
After the pandemic, public trust in the U.S. healthcare system plummeted, and officials at the local level took the hardest hit when compared to federal health officials. As things stand, even state and federal health officials are losing even the little trust that the public still had in them. For a healthcare system to function, public trust is vital because people want to believe that the professionals they entrust with their health have their best interests at heart.
Via Investor Brand Network · December 11, 2025
BioMedNewsBreaks — Caring Brands, Inc. (NASDAQ: CABR) Closes $4 Million Offering as Company Uplists to Nasdaq Capital Market
Caring Brands (NASDAQ: CABR) closed its underwritten U.S. public offering of 1,000,000 shares of common stock at $4.00 per share for gross proceeds of about $4 million before underwriting discounts and expenses, completing the Company’s uplisting to the Nasdaq Capital Market, where its shares began trading on Nov. 13, 2025. Caring Brands granted the underwriter a 45-day option to purchase up to 150,000 additional shares and intends to use net proceeds for general working capital, marketing and sales of its proprietary products, and repayment of certain debt.
Via Investor Brand Network · December 9, 2025